Loading...
Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray c...
Na minha lista:
Udgivet i: | Neoplasia |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Neoplasia Press
2017
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5565634/ https://ncbi.nlm.nih.gov/pubmed/28830008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.06.003 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|